---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025554"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2026-05-28T13:11:20+00:00"
generated_at: "2026-05-28T13:48:47.467273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic and Scripps Research collaborate on hantavirus antibody and vaccine development using C1 platform

## Summary
- Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus causing Hantavirus Pulmonary Syndrome.
- Builds on prior Andes virus monoclonal antibody work; C1 platform aims for rapid, scalable biologic production.
- C1 platform previously applied to RSV, malaria, Andes, Ebola, Marburg; demonstrated comparable neutralization to mammalian systems.
- Dyadic currently in funded collaborations with Gates Foundation, CEPI, and FBS for accelerating vaccine/antibody development.
- Parties plan to explore external partnership and non-dilutive funding opportunities to support further development.

## SEC filing metadata
- accession: 0001493152-26-025554
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2026-05-28T13:11:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315226025554/0001493152-26-025554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315226025554/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025554
- JSON: https://secwatch.observer/filing/0001493152-26-025554.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.